Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

10 settembre 2016 aggiornato da: Hoffmann-La Roche

A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy

This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination. Once disease progression is reported, all participants will be followed for survival every 3 months until death, loss to follow-up, withdrawal of consent, or study termination.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

991

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

  • Bosnia Erzegovina
      • Banja Luka, Bosnia Erzegovina, 78000
      • Sarajewo, Bosnia Erzegovina, 71000
  • Brasile
      • Belo Horizonte, Brasile, 30150-281
      • Curitiba, Brasile, 80530-010
      • Goiania, Brasile, 74605-070
      • Itajai, Brasile, 88301-220
      • JAU, Brasile, 17210-080
      • Joao Pessoa, Brasile, 58040280
      • Porto Alegre, Brasile, 90610-000
      • Porto Alegre, Brasile, 91350-200
      • Porto Alegre, Brasile, 90430-090
      • Porto Alegre - Rs, Brasile, 90050-170
      • Rio de Janeiro, Brasile, 20560-120
      • Rio de Janeiro, Brasile, 22260-020
      • Santo Andre, Brasile, 09060-870
      • Sao Paulo, Brasile, 1323020
      • Sao Paulo, Brasile, 01317-000
  • Bulgaria
      • Plovdiv, Bulgaria, 4000
      • Sofia, Bulgaria, 1756
      • Sofia, Bulgaria, 1784
      • Varna, Bulgaria, 9002
  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 4N2
      • Edmonton, Alberta, Canada, T6G 1Z2
    • British Columbia
      • Kelowna, British Columbia, Canada, V1Y 5L3
      • Vancouver, British Columbia, Canada, V5Z 1H5
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2Y9
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
      • Sudbury, Ontario, Canada, J9P 3Y1
      • Toronto, Ontario, Canada, M4N 3M5
    • Quebec
      • Greenfield Park, Quebec, Canada, J4V 2H1
      • Montreal, Quebec, Canada, H1T 2M4
      • Montreal, Quebec, Canada, H3T 1E2
      • Montreal, Quebec, Canada, H2W 1T8
  • Colombia
      • Bogota, Colombia
      • Bogota, Colombia, 49 00
      • Monteria, Colombia
  • Corea, Repubblica di
      • Kyunggi-do, Corea, Repubblica di, 411-769
      • Seoul, Corea, Repubblica di, 110-744
      • Seoul, Corea, Repubblica di, 120-752
      • Seoul, Corea, Repubblica di, 135-710
  • Danimarca
      • Herlev, Danimarca, 2730
      • København, Danimarca, 2100
      • Odense, Danimarca, 5000
  • Federazione Russa
      • Kemerovo, Federazione Russa, 650036
      • Moscow, Federazione Russa, 121356
      • St Petersburg, Federazione Russa, 197758
  • Filippine
      • Diliman, Quezon City, Filippine, 1100
      • Quezon City, Luzon, Filippine, 1101
  • Finlandia
      • Helsinki, Finlandia, 00180
      • Tampere, Finlandia, 33520
      • Turku, Finlandia, 20520
  • Francia
      • Avignon, Francia, 84082
      • Bordeaux, Francia, 33076
      • Brest, Francia, 29609
      • Caen, Francia, 14076
      • Dijon, Francia, 21079
      • La Roche Sur Yon, Francia, 85925
      • Montpellier, Francia, 34298
      • Paris, Francia, 75248
      • Saint Brieuc, Francia, 22015
      • Saint Herblain, Francia, 44805
      • Vandoeuvre-les-nancy, Francia, 54511
  • Germania
      • Aschaffenburg, Germania, 63739
      • Berlin, Germania, 10367
      • Berlin, Germania, 13125
      • Berlin, Germania, 4169
      • Bonn, Germania, 53113
      • Dortmund, Germania, 44137
      • Freiburg, Germania, 79106
      • Fuerstenwalde, Germania, 15517
      • Hamburg, Germania, 20357
      • Karlsruhe, Germania, 76135
      • Kiel, Germania, 24105
      • Offenbach, Germania, 63069
      • Stralsund, Germania, 18435
  • Hong Kong
      • Hong Kong, Hong Kong
  • India
      • Bangalore, India, 560027
      • Gurgaon, India, 122001
      • Kolkata, India, 700 053
      • New Delhi, India, 110029
      • Pune, India, 411004
  • Italia
      • Aviano, Italia, 33081
      • Bologna, Italia, 40138
      • Candiolo, Italia, 10060
      • Genova, Italia, 16132
      • Meldola, Italia, 47014
      • Milano, Italia, 20133
      • Milano, Italia, 20141
      • Napoli, Italia, 80131
      • Negrar, Italia, 37024
      • Pisa, Italia, 56100
      • Reggio Emilia, Italia, 42100
      • Roma, Italia, 00168
      • Rozzano, Italia, 20089
      • Sassari, Italia, 07100
      • Terni, Italia, 05100
  • Messico
      • Acapulco, Messico, 39670
      • Oaxaca, Messico, 68000
      • Toluca, Messico, 50180
  • Nuova Zelanda
      • Newtown, Nuova Zelanda, 6021
      • Palmerston North, Nuova Zelanda, 4442
  • Polonia
      • Bialystok, Polonia, 15-027
      • Gdansk, Polonia, 80-952
      • Krakow, Polonia, 31-531
      • Lublin, Polonia, 20-090
      • Opole, Polonia, 45-060
      • Poznan, Polonia, 61-866
      • Warszawa, Polonia, 02-781
  • Portogallo
      • Coimbra, Portogallo, 3000-075
      • Lisboa, Portogallo, 1649-035
      • Porto, Portogallo, 4200-072
  • Regno Unito
      • Bournemouth, Regno Unito, BH7 7DW
      • Cardiff, Regno Unito, CF14 2TL
      • Denbigh, Regno Unito, LL18 5UJ
      • London, Regno Unito, SE1 7EH
      • London, Regno Unito, SW3 6JJ
      • Manchester, Regno Unito, M20 4BX
      • New Castle Upon Tyne, Regno Unito, NE7 7DN
      • Northwood, Regno Unito, HA6 2RN
      • Poole, Regno Unito, BH15 2JB
      • Preston, Regno Unito, PR2 9HT
      • Romford, Regno Unito, RM7 0AG
      • Sutton, Regno Unito, SM2 5PT
      • Weston Super Mare, Regno Unito, BS23 4TQ
  • Singapore
      • Singapore, Singapore, 119074
      • Singapore, Singapore, 169610
  • Slovenia
      • Ljubljana, Slovenia, 1000
  • Spagna
      • Barcelona, Spagna, 08035
      • Córdoba, Spagna, 14004
      • Lerida, Spagna, 25198
      • Madrid, Spagna, 28046
      • Madrid, Spagna, 28041
      • Santander, Spagna, 39008
      • Sevilla, Spagna, 41013
      • Valencia, Spagna, 46009
      • Zaragoza, Spagna, 50009
  • Stati Uniti
    • Arizona
      • Chandler, Arizona, Stati Uniti, 85224
      • Tucson, Arizona, Stati Uniti, 85719
    • California
      • Anaheim, California, Stati Uniti, 92801
      • Anaheim, California, Stati Uniti, 92807
      • Bakersfield, California, Stati Uniti, 93309
      • Baldwin Park, California, Stati Uniti, 91706
      • Bellflower, California, Stati Uniti, 90706
      • Duarte, California, Stati Uniti, 91010
      • Fontana, California, Stati Uniti, 92335
      • Hayward, California, Stati Uniti, 94545
      • Irvine, California, Stati Uniti, 92618
      • La Jolla, California, Stati Uniti, 92093
      • La Mesa, California, Stati Uniti, 91942
      • Loma Linda, California, Stati Uniti, 92354
      • Long Beach, California, Stati Uniti, 90806
      • Los Angeles, California, Stati Uniti, 90025
      • Los Angeles, California, Stati Uniti, 90057
      • Los Angeles, California, Stati Uniti, 90095-1772
      • Los Angeles, California, Stati Uniti, 90034
      • Montebello, California, Stati Uniti, 90640
      • Newport Beach, California, Stati Uniti, 92660
      • Oakland, California, Stati Uniti, 94611
      • Panorama City, California, Stati Uniti, 91402
      • Riverside, California, Stati Uniti, 92505
      • Roseville, California, Stati Uniti, 95661
      • Sacramento, California, Stati Uniti, 95825
      • San Diego, California, Stati Uniti, 92123
      • San Diego, California, Stati Uniti, 92120
      • San Francisco, California, Stati Uniti, 94115
      • San Jose, California, Stati Uniti, 95119
      • Santa Clara, California, Stati Uniti, 95051
      • Santa Maria, California, Stati Uniti, 93454
      • Santa Monica, California, Stati Uniti, 90404
      • South San Francisco, California, Stati Uniti, 94080
      • Thousand Oaks, California, Stati Uniti, 91360
      • Vallejo, California, Stati Uniti, 94589
      • Walnut Creek, California, Stati Uniti, 94596
      • Woodland Hills, California, Stati Uniti, 91367
    • Colorado
      • Fort Collins, Colorado, Stati Uniti, 80528
    • Connecticut
      • Norwalk, Connecticut, Stati Uniti, 06856
      • Norwich, Connecticut, Stati Uniti, 06360
      • Stamford, Connecticut, Stati Uniti, 06902
    • District of Columbia
      • Washington, District of Columbia, Stati Uniti, 20010
    • Florida
      • Boca Raton, Florida, Stati Uniti, 33486
      • Fernandina Beach, Florida, Stati Uniti, 32034
      • Fort Myers, Florida, Stati Uniti, 33916
      • Ft. Lauderdale, Florida, Stati Uniti, 33316
      • Hollywood, Florida, Stati Uniti, 33021
      • Jacksonville, Florida, Stati Uniti, 32205
      • Jacksonville, Florida, Stati Uniti, 32256
      • Jacksonville, Florida, Stati Uniti, 32207
      • Jacksonville, Florida, Stati Uniti, 32258
      • Kissimmee, Florida, Stati Uniti, 34741
      • Lakeland, Florida, Stati Uniti, 33804-1057
      • Miami, Florida, Stati Uniti, 33136
      • Miami, Florida, Stati Uniti, 33176
      • Miami, Florida, Stati Uniti, 33133
      • Orange Park, Florida, Stati Uniti, 32073
      • Pembroke Pines, Florida, Stati Uniti, 33028
    • Georgia
      • Athens, Georgia, Stati Uniti, 30607
      • Atlanta, Georgia, Stati Uniti, 30342
      • Atlanta, Georgia, Stati Uniti, 30322
      • Atlanta, Georgia, Stati Uniti, 30341
      • Atlanta, Georgia, Stati Uniti, 30318
      • Carrolton, Georgia, Stati Uniti, 30117
      • Cartersville, Georgia, Stati Uniti, 30121
      • Decatur, Georgia, Stati Uniti, 30033
      • Douglasville, Georgia, Stati Uniti, 30134
      • Macon, Georgia, Stati Uniti, 31217
      • Marietta, Georgia, Stati Uniti, 30060
    • Idaho
      • Boise, Idaho, Stati Uniti, 83712
      • Meridian, Idaho, Stati Uniti, 83642
      • Nampa, Idaho, Stati Uniti, 83686
      • Post Falls, Idaho, Stati Uniti, 83854
      • Twin Falls, Idaho, Stati Uniti, 83301
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60612
      • Decatur, Illinois, Stati Uniti, 62526
      • Effingham, Illinois, Stati Uniti, 62526
      • Joliet, Illinois, Stati Uniti, 60435
      • Morris, Illinois, Stati Uniti, 60450
      • Peoria, Illinois, Stati Uniti, 61615-7828
      • Skokie, Illinois, Stati Uniti, 60076
      • Zion, Illinois, Stati Uniti, 60099
    • Iowa
      • Bettendorf, Iowa, Stati Uniti, 52722
    • Kansas
      • Wichita, Kansas, Stati Uniti, 67214-3728
    • Kentucky
      • Paducah, Kentucky, Stati Uniti, 42001
    • Louisiana
      • Covington, Louisiana, Stati Uniti, 70433
      • Lafayette, Louisiana, Stati Uniti, 70503
      • Marrero, Louisiana, Stati Uniti, 70072
      • Metairie, Louisiana, Stati Uniti, 70006
      • New Orleans, Louisiana, Stati Uniti, 70115
    • Maine
      • Kittery, Maine, Stati Uniti, 03904
      • Wells, Maine, Stati Uniti, 04090
      • York, Maine, Stati Uniti, 03909
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21202
      • Baltimore, Maryland, Stati Uniti, 21237
      • Bethesda, Maryland, Stati Uniti, 20817
      • Rockville, Maryland, Stati Uniti, 20850
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
      • Boston, Massachusetts, Stati Uniti, 02114
      • Boston, Massachusetts, Stati Uniti, 02118
      • Boston, Massachusetts, Stati Uniti, 02115
      • Burlington, Massachusetts, Stati Uniti, 01805
      • Peabody, Massachusetts, Stati Uniti, 01960
    • Michigan
      • Brownstown, Michigan, Stati Uniti, 48183
      • Dearborn, Michigan, Stati Uniti, 48126
      • Detroit, Michigan, Stati Uniti, 48201
      • Detroit, Michigan, Stati Uniti, 48202
      • Saint Joseph, Michigan, Stati Uniti, 49085
      • West Bloomfield, Michigan, Stati Uniti, 48322
    • Minnesota
      • Edina, Minnesota, Stati Uniti, 55414
      • Maplewood, Minnesota, Stati Uniti, 55109
      • Minneapolis, Minnesota, Stati Uniti, 55454
      • Saint Louis Park, Minnesota, Stati Uniti, 55426
      • Saint Paul, Minnesota, Stati Uniti, 55101
      • St. Louis Park, Minnesota, Stati Uniti, 55426
    • Missouri
      • Joplin, Missouri, Stati Uniti, 64804
      • Kansas City, Missouri, Stati Uniti, 64111
      • Saint Louis, Missouri, Stati Uniti, 63110
      • Saint Peters, Missouri, Stati Uniti, 63110
      • St. Louis, Missouri, Stati Uniti, 63141
      • St. Peters, Missouri, Stati Uniti, 63376
    • Montana
      • Missoula, Montana, Stati Uniti, 59802
    • Nebraska
      • Omaha, Nebraska, Stati Uniti, 68114
    • Nevada
      • Henderson, Nevada, Stati Uniti, 89052
    • New Jersey
      • Cherry Hill, New Jersey, Stati Uniti, 08002
      • Hackensack, New Jersey, Stati Uniti, 07601
      • Morristown, New Jersey, Stati Uniti, 07962
      • Parsippany, New Jersey, Stati Uniti, 07054
      • Voorhees, New Jersey, Stati Uniti, 08043
    • New Mexico
      • Santa Fe, New Mexico, Stati Uniti, 87505
    • New York
      • Brockport, New York, Stati Uniti, 14420
      • Canandaigua, New York, Stati Uniti, 14424
      • Fresh Meadows, New York, Stati Uniti, 11366
      • Geneva, New York, Stati Uniti, 14456
      • Greece, New York, Stati Uniti, 14626
      • Lake Success, New York, Stati Uniti, 11042
      • Mount Kisco, New York, Stati Uniti, 10549
      • Rochester, New York, Stati Uniti, 14626
      • Stony Brook, New York, Stati Uniti, 11794
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28203
      • Durham, North Carolina, Stati Uniti, 27710
      • Hickory, North Carolina, Stati Uniti, 28602
      • Kinston, North Carolina, Stati Uniti, 28501
      • Washington, North Carolina, Stati Uniti, 27889
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44195
      • Cleveland, Ohio, Stati Uniti, 44106
      • Columbus, Ohio, Stati Uniti, 43215
      • Columbus, Ohio, Stati Uniti, 43219
      • Columbus, Ohio, Stati Uniti, 43228
      • Middletown, Ohio, Stati Uniti, 45042
      • Newark, Ohio, Stati Uniti, 43055
      • Sandusky, Ohio, Stati Uniti, 44870
    • Oregon
      • Portland, Oregon, Stati Uniti, 97227
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19124
      • Philadelphia, Pennsylvania, Stati Uniti, 19106
      • Pittsburgh, Pennsylvania, Stati Uniti, 15232
      • Pittsburgh, Pennsylvania, Stati Uniti, 15213
    • Rhode Island
      • East Providence, Rhode Island, Stati Uniti, 02915
    • South Carolina
      • Columbia, South Carolina, Stati Uniti, 29210
      • North Charleston, South Carolina, Stati Uniti, 29425
    • Tennessee
      • Memphis, Tennessee, Stati Uniti, 38120
      • Nashville, Tennessee, Stati Uniti, 37203
    • Texas
      • Austin, Texas, Stati Uniti, 78731
      • Bryan, Texas, Stati Uniti, 77802
      • Cypress, Texas, Stati Uniti, 77429
      • Dallas, Texas, Stati Uniti, 75230
      • El Paso, Texas, Stati Uniti, 79902
      • Houston, Texas, Stati Uniti, 77090
      • Shenandoah, Texas, Stati Uniti, 77384
      • Temple, Texas, Stati Uniti, 76501
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22031
    • Washington
      • Gig Harbor, Washington, Stati Uniti, 98332
      • Lakewood, Washington, Stati Uniti, 98499
      • Puyallup, Washington, Stati Uniti, 98372
      • Tacoma, Washington, Stati Uniti, 98405
    • Wisconsin
      • Milwaukee, Wisconsin, Stati Uniti, 53226
      • Wausau, Wisconsin, Stati Uniti, 54401
  • Svezia
      • Eskilstuna, Svezia, 63188
      • Gaelve, Svezia, 80187
      • Goteborg, Svezia, 40036
  • Svizzera
      • Luzern, Svizzera, 6004
      • St. Gallen, Svizzera, 9007
  • Taiwan
      • Kaohsung, Taiwan, 883
      • Taichung, Taiwan, 404
      • Taichung, Taiwan, 407
      • Taipei, Taiwan, 112
      • Taoyuan, Taiwan, 333

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • HER2 status must be prospectively, centrally tested and be HER2-positive based on central laboratory assay results
  • Histologically or cytologically confirmed invasive breast cancer
  • Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both a taxane, alone or in combination with another agent, and trastuzumab, alone or in combination with another agent
  • Documented progression (which occur during or after most recent treatment or within 6 months after completing of adjuvant therapy) of incurable, unresectable, locally advanced or metastatic breast cancer, defined by the investigator
  • Measurable and/or nonmeasurable disease; participants with central nervous system-only disease are excluded
  • Cardiac ejection fraction greater than or equal to (>/=) 50 percent (%) by either echocardiogram or multi-gated acquisition scan
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception; contraception use should continue for the duration of the study treatment and for at least 6 months after the last dose of study treatment

Exclusion Criteria:

  • History of treatment with trastuzumab emtansine
  • Prior treatment with lapatinib or capecitabine
  • Peripheral neuropathy of Grade >/= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0
  • History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer, or cancers with a similar curative outcome as those mentioned above
  • History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to randomization except hormone therapy, which could be given up to 7 days prior to randomization; recovery of treatment-related toxicity consistent with other eligibility criteria
  • History of radiation therapy within 14 days of randomization
  • Brain metastases that are untreated, symptomatic, or require therapy to control symptoms, as well as any history of radiation, surgery, or other therapy, including steroids, to control symptoms from brain metastases within 2 months (60 days) of randomization
  • History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment
  • History of myocardial infarction or unstable angina within 6 months of randomization
  • Current dyspnea at rest due to complications of advanced malignancy or current requirement for continuous oxygen therapy
  • Current severe, uncontrolled systemic disease (for example, clinically significant cardiovascular, pulmonary, or metabolic disease)
  • Pregnancy or lactation
  • Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
  • Presence of conditions that could affect gastrointestinal absorption: Malabsorption syndrome, resection of the small bowel or stomach, and ulcerative colitis
  • History of intolerance (such as Grade 3-4 infusion reaction) to trastuzumab
  • Known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase deficiency
  • Current treatment with sorivudine or its chemically related analogs, such as brivudine

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Trastuzumab emtansine
Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
Droga: Trastuzumab emtansine
Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
Altri nomi:
  • RO5304020
  • T-DM1
  • Trastuzumab-MCC-DM1
Comparatore attivo: Lapatinib + Capecitabine
Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.
Droga: Lapatinib
Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
Altri nomi:
  • Tykerb
  • Tiverbo
Droga: Capecitabine
Capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
Altri nomi:
  • Xeloda

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)
Lasso di tempo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PD was assessed by an IRC using modified Response Evaluation Criteria in Solid Tumors (RECIST). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as target lesions (TLs) and recorded at baseline. TLs should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements either by imaging or clinically. A sum of the longest diameter for all TLs was calculated as baseline sum longest diameter (SLD). All other lesions (or sites of disease) should be identified as non-TLs and recorded at baseline. PD for TLs was defined as greater than or equal to (>/=) 20 percent (%) increase in SLD, taking as reference smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of Participants with PD by IRC or death from any cause was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)
Lasso di tempo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs (on the basis of their size and their suitability for accurate repeated measurements either by imaging or clinically) and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. All other lesions were identified as non-TLs and recorded at baseline. PD for TLs: >/= 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS: time from randomization to first documented PD by IRC or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% confidence interval (CI) was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants Who Died: Second Interim Analysis
Lasso di tempo: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
The percentage of participants who died from any cause was reported. The results are reported from second interim analysis, which deemed to be the confirmatory.
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Overall Survival: Second Interim Analysis (Co-primary Endpoint)
Lasso di tempo: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results are reported from second interim analysis, which deemed to be the confirmatory.
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Percentage of Participants Who Died: Final Analysis
Lasso di tempo: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
The percentage of participants who died from any cause was reported. The results reported are from the final analysis. The final analysis is descriptive.
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Overall Survival: Final Analysis
Lasso di tempo: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results reported are from the final analysis. The final analysis is descriptive.
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Percentage of Participants Who Were Alive at Year 1
Lasso di tempo: Year 1
1 year survival was defined as the percentage of participants alive 1 year after starting treatment. The results reported are from the final analysis.
Year 1
Percentage of Participants Who Were Alive at Year 2
Lasso di tempo: Year 2
2 year survival was defined as the percentage of participants alive 2 years after starting treatment. The results reported are from the final analysis.
Year 2

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants With PD or Death as Assessed by the Investigator
Lasso di tempo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PD was assessed by the investigator using modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The percentage of participants who died or experienced PD by Investigator was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PFS as Assessed by the Investigator
Lasso di tempo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by the investigator according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS was defined as the time from randomization to first documented PD by Investigator or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Objective Response (OR) as Assessed by an IRC
Lasso di tempo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. OR was defined as the percentage of participants with a complete response (CR) or partial response (PR). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as >/= 30% decrease in the SLD of TLs, taking as reference the baseline SLD. For non-TLs, a CR was defined as the disappearance of all non-TLs and a PR was defined as the persistence of 1 or more non-TLs. Confirmation of response at a consecutive tumor assessment at least 4 weeks apart was required. Participants without a post-baseline tumor assessment were considered non-responders. The percentage of participants with CR or PR by IRC was reported. The 95% CI was computed using Blyth-Still Casella exact CI method.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Duration of Objective Response (DOR) as Assessed by an IRC
Lasso di tempo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier. OR was defined as a CR or PR determined on 2 consecutive tumor assessments at least 4 weeks apart. For TLs, CR was defined as the disappearance of all TLs; PR was defined as >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; and PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, CR was defined as the disappearance of all non-TLs; PR was defined as the persistence of 1 or more non-TLs; and PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Clinical Benefit as Assessed by an IRC
Lasso di tempo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. Participants were considered as experienced clinical benefit if they had an OR or maintained stable disease (SD) for at least 6 months from randomization. OR: CR or PR determined on 2 consecutive tumor assessments >/=4 weeks apart. For TLs, CR: disappearance of all TLs; PR: >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; PD: >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions; and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For non-TLs, CR: disappearance of all non-TLs; PR/SD: persistence of 1 or more non-TLs; and PD: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Participants without a post-baseline tumor assessment were considered non-responders. The 95% CI was computed using Blyth-Still Casella exact CI method.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Treatment Failure
Lasso di tempo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Treatment failure was defined as discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of participants with treatment failure was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to Treatment Failure
Lasso di tempo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to treatment failure was defined as the time from randomization to discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued with treatment failure date as the later of the 2 discontinuation dates. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The median time to treatment failure was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Symptom Progression
Lasso di tempo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Symptom progression was defined as the documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the Functional Assessment of Cancer Therapy-for participants with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (breast cancer subscale [BCS]). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The percentage of participants with symptom progression was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to Symptom Progression
Lasso di tempo: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to symptom progression was defined as the time from randomization to the first documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the FACT-B questionnaire with the TOI-PFB subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (BCS). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The median time to symptom progression was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Hoffmann-La Roche

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 febbraio 2009

Completamento primario (Effettivo)

1 luglio 2012

Completamento dello studio (Effettivo)

1 settembre 2015

Date di iscrizione allo studio

Primo inviato

22 gennaio 2009

Primo inviato che soddisfa i criteri di controllo qualità

22 gennaio 2009

Primo Inserito (Stima)

26 gennaio 2009

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

31 ottobre 2016

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 settembre 2016

Ultimo verificato

1 settembre 2016

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • BO21977
  • TDM4370g (Altro identificatore: Genentech)

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Cancro al seno

Prove cliniche su Trastuzumab emtansine

Cerca prove simili

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

CROs by country

CROs in Tunisia

Condizioni

Malattie rare

Interventi farmacologici

Supplementi dietetici

Sponsor / Collaboratori

Sedi

Sottoscrivi